Tag: biomarkers

Letters to the Editor: What About Biomarkers for Parkinson’s Disease?

Letters to the Editor: What About Biomarkers for Parkinson’s Disease?

| January 1, 2021

Dear Editor: Parkinson’s disease (PD) affects over 600,000 patients in the United States; these numbers might double by 2040, as the population of older people increases.1 Diagnostic clues include the signs of resting tremor, bradykinesia, muscle rigidity, and postural imbalance. However, these clinical indicators might be inaccurate much of the time. A low rate of […]

Continue Reading

Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin

Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin

| January 1, 2021

by Evangelia Bountouvi, MD, PhD; Melpomeni Giorgi, MD; Anna Papadopoulou, PhD; Kaj Blennow, PhD; Ingemar Björkhem, PhD; Maria Tsirouda, PhD; Spyridon Kanellakis, Msc, PhD; Andreas Fryganas, MD; Maria Spanou, MD; Ioanna Georgaki, MD; Sofia Asprogeraka, MD; and Argyrios Dinopoulos, PhD Drs. Bountouvi, Giorgi, Papadopoulou, Tsirouda, Fryganas, Spanou, Georgaki, Asprogeraka, and Dinopoulos are with the Third […]

Continue Reading

Clinical Implications of the New Diagnostic Guidelines for Dementia

Clinical Implications of the New Diagnostic Guidelines for Dementia

| June 10, 2013 | 0 Comments

by Edmund Howe, MD, JD Dr. Howe is Professor, Department of Psychiatry, Director, Programs in Medical Ethics, and Senior Scientist, Center for the Study of Traumatic Stress, Uniformed Services University of the Health Sciences, Bethesda, Maryland. Innov Clin Neurosci. 2013;10(5–6):32–38

Continue Reading